Macular Holes
Conditions
Brief summary
The main objective of this study is to evaluate the therapeutic effectiveness of the internal limiting membrane (ILM) peeling and translocation surgery compared to the conventional surgical approach for treating large idiopathic macular hole (IMH) through a well-designed prospective randomized controlled clinical trial. This study aims to compare the new surgical approach to the conventional approach in terms of improving visual function, promoting macular retinal anatomical healing, and enhancing patients' quality of life. By conducting this prospective clinical trial, establishing a database, and generating clinical reports and evidence-based medicine on the therapeutic efficacy of the ILM peeling and translocation surgery for large IMH.
Interventions
PROCEDURETranslocation ILM Flap
After vitrectomy, the ILM was dissected from the macula to the vascular arch, and the retina in the fissure area was fully released to make an MH-centered, approximately 2DD-square, ILM flap with a tip (approximately 500μm wide) above; the ILM flap was transposed approximately 25-30 degrees along the tip to the inferior temporal area with the assistance of heavy water, and a total of 1ml of perfluorodecalin fluid (heavy water) was injected to cover the MH area with the ILM flap, and the original ILM defect area corresponding to the MH was transposed to the outside of the MH. The heavy water is replaced by liquid/gas exchange. Ophthalmic 13% perfluoropropane gas (AL.CHI.MI.A. Srl) was chosen as the postoperative intraocular filling.
PROCEDUREILM Peeling
After vitrectomy, internal limiting membrane peeling up to the vascular arcade, thorough loosening of the macular hole area of the retina, and fluid/gas exchange. An eye-specific 13% perfluoropropane gas (AL.CHI.MI.A. Srl) was chosen for intraocular tamponade after the operation.
Sponsors
Shanghai Municipal Science and Technology Commission
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
55 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Participants who can understand the purpose of this clinical trial, volunteer to participate, sign an informed consent form, and can complete the postoperative follow-up on time. * Participants diagnosed with idiopathic macular hole (IMH). * Based on OCT scans, the minimum horizontal diameter of the macular hole is \>500 and \<900 µm. * Participants with an axial length \<26.0mm and a myopic degree lower than 6D. * For participants with bilateral macular holes, the eye with a larger hole diameter will be included.
Exclusion criteria
* Patients with the following retinal disorders: age-related macular degeneration, epi-macular membrane neovascularization, non-macular retinal tears, lesions of the retinal pigment epithelium and choroid, inherited or degenerative retinal diseases, optic neuropathies, retinal vascular diseases; patients with large macular holes accompanied by retinal detachment; * Patients with high myopia (axial length ≥ 26.0mm and myopia exceeding 6D); * Patients with a history of ocular trauma or retinal laser treatment; * Patients with glaucoma, ocular infections, inflammations, tumors, corneal diseases, or amblyopia; * Patients with contraindications to vitrectomy; * Patients with severe or unstable systemic diseases; * Patients with a fasting blood glucose level ≥ 9mmol/L before surgery; * Patients who participated in other clinical trials involving drugs or medical devices within 30 days prior to screening; * Patients with a history of intraocular surgery within 3 months prior to screening; * Patients with reduced visual function or vision in the contralateral eye as determined by the investigator; * Patients who are not considered suitable for enrollment by the investigator for other reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Best Corrected Visual Acuity | 1 week, 1 month, 3 months, 1 years, 2 years after the operation | The best corrected visual acuity indicates the best visual acuity with proper refractive correction. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Closure rate | 1 week, 1 month, 3 months, 1 years, 2 years after the operation | MH closure is mainly reflected in the outer layer of continuity closure shown on OCT. |
Countries
China
Contacts
Primary ContactPeiquan Zhao, Dr.
Backup ContactJiao Lyu, Dr.
Outcome results
None listed